Akademik Veri Yönetim Sistemi
Applications of Chemistry in Nanosciences and Biomaterials Engineering NanoBioMat 2023 – Summer Edition, Bucuresti, Romanya, 26 - 30 Haziran 2023, ss.47-48
Epilepsy is the most common neurological disease that affected people of all ages, races, social classes,
and geographical locations. According to the 2019 World Health Organization (WHO) data, about 0.7 % of
the population is struggling with epilepsy. In addition, nearly 5 million people are diagnosed every year.
The basic characteristic of epilepsy is aberrant electrical activity in several brain regions. About %70
patients with epilepsy can be treated successfully with antiepileptic drugs to control the patient's seizures.
20–30% of patients exhibit pharmacoresistance, and only a small portion of these patients will benefit from
surgical intervention. Therefore, developing a successful treatment for the disease is still quite difficult. To
accomplish this objective, antiepileptic drug-loaded carrier nanoparticles can be an alternative treatment for
epilepsy.Recent developments to improve the release of drugs from smart materials include Near Infrared
Light (NIR) radiation (NIR), ultraviolet (UV) and visible wavelength light, magnetic fields, ultrasound, and
electrical stimulation. Compared to drug delivery systems based on stable passive delivery, these strategies
offer more effective control over the delivery of drugs. Nanoparticle drug carriers are being studied further
for controlled drug delivery due to their benefits including good structure and tunable characteristics.
Multiferroic materials due to their controllable possession, have drawn interest in recent years to develop
new materials or structures. Bismuth ferrite (BiFeO3, BFO) is a single-phase multiferroic material with a
polar R3c space group and rhombohedral distorted cell, has the ability to be both ferroelectric and antiferromagnetic.In this study, bare and drug loaded bismuth ferrite nanoparticles were synthesized by coprecipitation method. Bare and drug loaded nanoparticles were characterized by fourier transform infrared
spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray diffraction analysis (XRD), and
scanning electron microscopy (SEM). Ethosuximide is an FDA-approved, made available as an efficient
and generally well-tolerated medication to treat absence seizures. It prevents clonic seizures generated on
by bicuculline or pentylenetetrazole when administered subcutaneously. Also, biological test was done by
using microglia cells.